Trials / Completed
CompletedNCT06855147
Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects
A Single-center, Open-label, Phase Ⅰ Clinical Study of the Absorption, Metabolism, and Excretion of [14C]HRS9531 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study was a single-center, single-dose, open-label study in healthy male subjects to investigate the absorption, metabolism and excretion of HRS9531 after a single subcutaneous injection of \[14C\]HRS9531.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]HRS9531 | A single dose of \[14C\]HRS9531 injected subcutaneously. |
Timeline
- Start date
- 2025-04-21
- Primary completion
- 2025-06-17
- Completion
- 2025-06-17
- First posted
- 2025-03-03
- Last updated
- 2025-07-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06855147. Inclusion in this directory is not an endorsement.